CAS 120993-53-5|Desirudin
Introduction：Basic information about CAS 120993-53-5|Desirudin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Desirudin | ||
|---|---|---|---|
| CAS Number | 120993-53-5 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | C287H440N80O110S6 | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Desirudin |
|---|
Desirudin BiologicalActivity
| Description | Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction[1][2]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Metabolic Enzyme/Protease >>Thrombin |
| Target | ED50: 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)[2]. |
| In Vivo | Desirudin (CGP 39393, 0.75-3.0 mg/kg, a bolus plus infusion administration, dogs model of cardiopulmonary bypass) is effective in Inhibiting clot formation[1]. Desirudin (0.01-1 mg/kg approximately, Intravenous injections and subcutaneous injection, rat shunt model) inhibits thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.), and inhibits venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)[2]. Animal Model: Male mongrel dogs model of cardiopulmonary bypass[1] Dosage: 1.0 mg/kg + 0.75 mg/kg/h, 1.0 mg/kg + 1.50 mg/kg/h, 1.0 mg/kg + 2.25 mg/kg/h, 1.0 mg/kg + 3.0 mg/kg/h. Administration: Administered as a bolus plus infusion Result: Inhibits clot formation with no adverse hemodynamic or hematologic effects. Animal Model: Rat shunt model of thrombus formation on a cotton-thread[2] Dosage: 0.01-1 mg/kg approximately Administration: Intravenous injections, subcutaneous injection Result: Inhibited thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.). Inhibited venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.). |
| References | [1]. J M Walenga, et al. Evaluation of CGP 39393 as the Anticoagulant in Cardiopulmonary Bypass Operation in a Dog Model. Ann Thorac Surg. 1994 Dec;58(6):1685-9. [2]. M D Talbot, et al. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost. 1989 Feb 28;61(1):77-80. |
Chemical & Physical Properties
| Molecular Formula | C287H440N80O110S6 |
|---|---|
| InChIKey | XYWBJDRHGNULKG-OUMQNGNKSA-N |
| SMILES | CCC(C)C1NC(=O)C2CSSCC(NC(=O)C(CC(C)C)NC(=O)C3CSSCC(NC(=O)C(CC(=O)O)NC(=O)C(NC(=O)C(Cc4ccc(O)cc4)NC(=O)C(NC(=O)C(N)C(C)C)C(C)C)C(C)O)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NCC(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)N3)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(C(C)C)C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)N3CCCC3C(=O)NC(CCC(N)=O)C(=O)NC(CO)C(=O)NC(Cc3cnc[nH]3)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(Cc3ccccc3)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)O)C(C)CC)C(C)O)C(C)O)C(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(C)C)NC1=O)C(=O)NCC(=O)NC(CCC(N)=O)C(=O)NCC(=O)NC(CC(N)=O)C(=O)NC(CCCCN)C(=O)N2 |
